Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)

M. Linch,C. Ferrario,M. Stoeckle,B. Laguerre,J. A. Arranz Arija, T. Todenhofer,P. C. Fong,J. M. Piulats Rodriguez,W. Berry,U. Emmenegger,L. Mourey, N. Mar,L. J. Appleman,A. Joshua, H. J. Conter, X. T. Li,C. Schloss, C. H. Poehlein, J. S. de Bono,E. Y. Yu

ANNALS OF ONCOLOGY（2022）

引用 0|浏览0

暂无评分

摘要

Initial analysis of Cohort D of the phase 1b/2 KEYNOTE-365 (NCT02861573) study showed pembro + abi and prednisone had antitumor activity and acceptable safety in patients (pts) with chemotherapy-naive mCRPC. Two-year follow-up is presented.

查看译文

关键词

pembrolizumab,prostate cancer,prednisone,two-year,chemotherapy-naive,castration-resistant

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要